Executive Team

Veriskin Core Team

With over 90 years of combined succesful medical development and entrepreneurial success, Veriskin, Inc. is transforming skin cancer screening by providing superior and precise technology to help patients and healthcare professionals detect skin cancer at the earliest visible signs.

Mirianas Chachisvilis PhD
Co-Founder CEO/CTO/Board Member

Prior to Veriskin, Dr. Mirianas Chachisvilis has served both as a faculty member in academia and in research and development roles in private enterprises. Dr. Chachisvilis has extensive academic experience, including training at Nobel Prize winning laboratory at California Institute of Technology. He has over 60 publications with multiple cited over 200 times. His research was supported by multiple research awards from the NIH and the NSF.
Carl_Edman
Carl Edman PhD
Co-Founder/Board Member

Dr. Carl Edman is an experienced early stage medical device executive, co-founder of PhiloMetron, Inc., a medical device incubator where he served as the Chief Scientific Officer. He successfully raised venture funds from high profile venture groups for Corventis (acquired by Medtronic) and Biocept. Dr. Edman also managed the initial product development and clinical trials at these organizations.
Eugene_Tu
Eugene Tu
Co-Founder/Board Member

Mr. Eugene Tu is a founding team member of multiple biotech startups including Nanogen, Genoptix, Nanomix, Omniome (just acquired by Pacific Biosciences of California, Inc. for $800M in July 2021) where Mr. Tu actively participated in fund raising and served as a key figure in the technical development of the respective technologies.
Autumn_Lang
Autumn Lang PhD
Director of Clinical Affairs/Operations

Autumn Lang, PhD has 22 years’ experience in a variety of clinical/regulatory and clinical affairs roles for medical devices and in CROs.
Jurgita_Jonutyte
Jurgita Jonutyte
Controller & Human Resources Manager

Jurgita Jonutyte brings over 20 years of accounting and HR experience working in the Biotech startups and private equity investment offices.